KASID
Search
- Page Path
- HOME > Search
Original Articles
- IBD
- Effects of COVID-19 vaccines on patient-reported outcomes in patients with inflammatory bowel disease: a multicenter survey study in Korea
- Jung Hyun Ji, Seung Hwan Shin, Yong Eun Park, Jihye Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim, Sang-Bum Kang, Sang Hyoung Park, Soo Jung Park, IBD Research Group of the Korean Association for the Study of Intestinal Diseases (KASID)
- Intest Res 2024;22(3):336-350. Published online March 26, 2024
- DOI: https://doi.org/10.5217/ir.2023.00077
-
Abstract
PDF
PubReader
ePub - Background/Aims
The impact of vaccination on inflammatory bowel disease (IBD) patients is still unknown, and no studies have assessed the changes in patient-reported outcomes (PROs) after vaccination in patients with IBD. Therefore, in this study, we investigated the impact of vaccines on the PROs of patients with IBD.
Methods
We conducted a questionnaire survey of patients with IBD who visited outpatient clinics at 4 specialized IBD clinics of referral university hospitals from April 2022 to June 2022. A total of 309 IBD patients were included in the study. Patient information was collected from a questionnaire and their medical records, including laboratory findings, were reviewed retrospectively. Risk factors associated with an increase in PROs after COVID-19 vaccination were analyzed using logistic regression analyses. In addition, we assessed whether there were differences in variables by vaccine order using the linear mixed model.
Results
In multivariate analysis, young age ( < 40 years) and ulcerative colitis (UC) were found to be independent risk factors for aggravation of PROs in patients with IBD. In all patients, platelet count significantly increased with continued vaccination in multiple pairwise comparisons. In UC patients, PROs such as the short health scale, UC-abdominal signs and symptoms, and UC-bowel signs and symptoms were aggravated significantly with continued vaccination. There was no significant increase in the variables of patients with Crohn’s disease.
Conclusions
Therefore, there may be a need to counsel patients with IBD younger than 40 years of age, and patients with UC before they receive COVID-19 vaccinations.
- 1,971 View
- 179 Download
- Colorectal neoplasia
- Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis
- Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
- Intest Res 2023;21(4):510-517. Published online May 31, 2023
- DOI: https://doi.org/10.5217/ir.2022.00139
-
Abstract
PDFPubReaderePub
- Background/Aims
Patients with more than 10 cumulative polyps might involve a greater genetic risk of colorectal neoplasia development. However, few studies have investigated the risk factors of polyposis recurrence and development of advanced neoplasms among patients with non-hereditary colorectal polyposis.
Methods
This study included patients (n=855) with 10 or more cumulative polyps diagnosed at Severance Hospital from January 2012 to September 2021. Patients with known genetic mutations related to polyposis, known hereditary polyposis syndromes, insufficient information, total colectomy, and less than 3 years of follow-up were excluded. Finally, 169 patients were included for analysis. We collected clinical data, including colonoscopy surveillance results, and performed Cox regression analyses of risk factors for polyposis recurrence and advanced neoplasm development.
Results
The 169 patients were predominantly male (84.02%), with a mean age of 64.19±9.92 years. The mean number of adenomas on index colonoscopy was 15.33±8.47. Multivariable analysis revealed history of cancer except colon cancer (hazard ratio [HR], 2.23; 95% confidence interval [CI], 1.23–4.01), current smoking (HR, 2.39; 95% CI, 1.17–4.87), and detection of many polyps (≥15) on index colonoscopy (HR, 2.05; 95% CI, 1.21–3.50) were significant risk factors for recurrence of polyposis. We found no statistically significant risk factors for advanced neoplasm development during surveillance among our cohort.
Conclusions
The presence of many polyps (≥15) on index colonoscopy, history of cancer except colon cancer, and current smoking state were significant risk factors for polyposis recurrence among patients with non-hereditary colorectal polyposis. -
Citations
Citations to this article as recorded by
- Screening and surveillance for hereditary colorectal cancer
Hee Man Kim, Tae Il Kim
Intestinal Research.2024; 22(2): 119. CrossRef
- Screening and surveillance for hereditary colorectal cancer
- 2,156 View
- 303 Download
- 1 Web of Science
- 1 Crossref
Perspective
- Miscellaneous
- Past, present, and future of Intestinal Research
- Jae Hee Cheon
- Intest Res 2023;21(1):1-2. Published online January 31, 2023
- DOI: https://doi.org/10.5217/ir.2023.00010
- 1,929 View
- 171 Download
Brief Communication
- IBD
- The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
- Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis
- Intest Res 2023;21(1):161-167. Published online April 18, 2022
- DOI: https://doi.org/10.5217/ir.2022.00006
-
PDF
Supplementary MaterialPubReaderePub -
Citations
Citations to this article as recorded by- New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases
Jihye Park, I. Seul Park, Ji Hyung Kim, Jung Hyun Ji, Soo Jung Park, Jae Jun Park, Tae Il Kim, Seung Won Kim, Jae Hee Cheon
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
- New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases
- 3,714 View
- 514 Download
- 1 Web of Science
- 1 Crossref
Brief Communcation
- IBD
- Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
- Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
- Intest Res 2021;19(4):478-481. Published online October 26, 2021
- DOI: https://doi.org/10.5217/ir.2021.00121
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by-
Expectations for employing
Escherichia coli
Nissle 1917 in food science and nutrition
Miaomiao Hu, Tao Zhang, Ming Miao, Kewen Li, Qingmin Luan, Guilian Sun
Critical Reviews in Food Science and Nutrition.2024; : 1. CrossRef - Potential of using an engineered indole lactic acid producing Escherichia coli Nissle 1917 in a murine model of colitis
Chrysoula Dimopoulou, Priscila Regina Guerra, Martin Steen Mortensen, Katja Ann Kristensen, Mikael Pedersen, Martin Iain Bahl, Morten Alexander Otto Sommer, Tine Rask Licht, Martin Frederik Laursen
Scientific Reports.2024;[Epub] CrossRef - Priority order of neonatal colonization by a probiotic or pathogenic Escherichia coli strain dictates the host response to experimental colitis
Tomas Hudcovic, Petra Petr Hermanova, Hana Kozakova, Oldrich Benada, Olga Kofronova, Martin Schwarzer, Dagmar Srutkova
Frontiers in Microbiology.2024;[Epub] CrossRef - Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model
Ji Hyung Kim, Jee In Yoo, Hyun Woo Ma, I Seul Park, Mijeong Son, Yoojin Shin, Ki Beom Kim, Seung Won Kim, Si Jae Park, Jihye Park
Intestinal Research.2023; 21(2): 266. CrossRef - Microbial Modulation in Inflammatory Bowel Diseases
Jongwook Yu, Jae Hee Cheon
Immune Network.2022;[Epub] CrossRef
-
Expectations for employing
Escherichia coli
Nissle 1917 in food science and nutrition
- 5,034 View
- 120 Download
- 5 Web of Science
- 5 Crossref
Brief Communication
- IBD
- Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice
- I Seul Park, Mijeong Son, Hyun Woo Ma, Jihyung Kim, Da Hye Kim, Seung Won Kim, Jae Hee Cheon
- Intest Res 2021;19(3):349-353. Published online November 2, 2020
- DOI: https://doi.org/10.5217/ir.2020.00075
-
Abstract
PDFPubReaderePub
- Background/Aims
The safety and effectiveness of adalimumab was demonstrated in a phase 3 trial in Japanese patients with intestinal Behçet’s disease. The aim of this study was to evaluate the long-term safety and effectiveness of adalimumab in Japanese patients with intestinal Behçet’s disease. -
Citations
Citations to this article as recorded by- Cellular succinate metabolism and signaling in inflammation: implications for therapeutic intervention
Hong Huang, Gejing Li, Yini He, Jing Chen, Jianye Yan, Qin Zhang, Liqing Li, Xiong Cai
Frontiers in Immunology.2024;[Epub] CrossRef - Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model
Ji Hyung Kim, Jee In Yoo, Hyun Woo Ma, I Seul Park, Mijeong Son, Yoojin Shin, Ki Beom Kim, Seung Won Kim, Si Jae Park, Jihye Park
Intestinal Research.2023; 21(2): 266. CrossRef - Succinate metabolism and its regulation of host-microbe interactions
Yi-han Wei, Xi Ma, Jiang-chao Zhao, Xiu-qi Wang, Chun-qi Gao
Gut Microbes.2023;[Epub] CrossRef - Urolithin A Alleviates Colitis in Mice by Improving Gut Microbiota Dysbiosis, Modulating Microbial Tryptophan Metabolism, and Triggering AhR Activation
Mingxia Ma, Yanxin Wang, Siqing Fan, Yumeng Huang, Xiurong Su, Chenyang Lu
Journal of Agricultural and Food Chemistry.2023; 71(20): 7710. CrossRef - Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
Gut and Liver.2023; 17(5): 766. CrossRef - Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
Gut and Liver.2023; 17(6): 905. CrossRef - Microbial Modulation in Inflammatory Bowel Diseases
Jongwook Yu, Jae Hee Cheon
Immune Network.2022;[Epub] CrossRef - Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
Intestinal Research.2021; 19(4): 478. CrossRef
- Cellular succinate metabolism and signaling in inflammation: implications for therapeutic intervention
- 4,689 View
- 163 Download
- 8 Web of Science
- 8 Crossref
Review
- Inflammatory bowel diseases
- Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases
- Jung Min Kim, Jae Hee Cheon
- Intest Res 2020;18(3):249-264. Published online April 18, 2020
- DOI: https://doi.org/10.5217/ir.2019.00128
-
Abstract
PDFPubReaderePub
- A considerable number of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), which can present either before or after IBD diagnosis. Unraveling the pathogenic pathways of EIMs in IBD is challenging because of the lack of reliable criteria for diagnosis and difficulty in distinguishing EIMs from external pathologies caused by drugs or other etiologies. Optimizing treatment can also be difficult. Early diagnosis and management of EIM revolve around multidisciplinary teams, and they should have the resources necessary to make and implement appropriate decisions. In addition, specialists of the affected organs should be trained in IBD treatment. Furthermore, patient awareness regarding the extraintestinal symptoms of IBD is of paramount importance for improving patient understanding of disease and health outcomes. Herein, we review the pathogenesis and clinical perspectives of EIMs in IBD.
-
Citations
Citations to this article as recorded by- Pomegranate seed oil mitigates liver and kidney damage in an experimental colitis model: Modulation of NF-κB activation and apoptosis
Açelya Gül Koyuncu, Alev Cumbul, Elvan Yilmaz Akyüz, Müge Kopuz Alvarez Noval
Prostaglandins & Other Lipid Mediators.2024; 171: 106804. CrossRef - Screening of silent inflammatory bowel disease in seronegative spondyloarthritis patients: Fecal calprotectin, ileo-colonoscopy and histopathology assessment
Shaimaa Badran, Andrew Saweres, Hadeel GamalEldeen, Mohamed B. Hashem, Dalia Abdel-kareem, Fatma H. Abdelraouf, Wafaa Gaber, Tamer Elbaz
The Egyptian Rheumatologist.2024; 46(1): 6. CrossRef - Leaky gut, circulating immune complexes, arthralgia, and arthritis in IBD: coincidence or inevitability?
Xi-ya Jin, Dan-dan Li, Wei Quan, Yang Chao, Bin Zhang
Frontiers in Immunology.2024;[Epub] CrossRef - Effect of ustekinumab on extraintestinal manifestations in patients with Crohn’s disease or ulcerative colitis
D. I. Abdulganieva, D. D. Mukhametova
Meditsinskiy sovet = Medical Council.2024; (8): 135. CrossRef - Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment
Ilaria Faggiani, Jacopo Fanizza, Ferdinando D’Amico, Mariangela Allocca, Alessandra Zilli, Tommaso Lorenzo Parigi, Alberto Barchi, Silvio Danese, Federica Furfaro
Biomedicines.2024; 12(8): 1839. CrossRef - Long‐term clinical outcomes of intestinal Behçet's disease: A 30‐year cohort study at a tertiary hospital in South Korea
Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2023; 38(3): 386. CrossRef - Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
Intestinal Research.2023; 21(2): 252. CrossRef - The Oral-Gut Axis: Periodontal Diseases and Gastrointestinal Disorders
Gretchen A Lam, Hala Albarrak, Cassidy J McColl, Alaina Pizarro, Harsha Sanaka, Adrian Gomez-Nguyen, Fabio Cominelli, Andre Paes Batista da Silva
Inflammatory Bowel Diseases.2023; 29(7): 1153. CrossRef - Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
So Jung Han, Eun Ae Kang, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Yonsei Medical Journal.2023; 64(2): 111. CrossRef - Are the risks of colorectal cancer and biliary cancer really increased if patients with ulcerative colitis have primary sclerosing cholangitis?
Jung Wook Lee, Won Moon
Intestinal Research.2023; 21(2): 171. CrossRef - The Relationship Between Rosacea and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Yu Kyung Jun, Da-Ae Yu, Yoo Min Han, Soo Ran Lee, Seong-Joon Koh, Hyunsun Park
Dermatology and Therapy.2023; 13(7): 1465. CrossRef - Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
Intestinal Research.2023; 21(4): 420. CrossRef - Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
Gut and Liver.2023; 17(5): 766. CrossRef - Regional variations in the prevalence of primary sclerosing cholangitis associated with inflammatory bowel disease
Kwang Woo Kim, Hyoun Woo Kang
Intestinal Research.2023; 21(4): 413. CrossRef - Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
Gut and Liver.2023; 17(6): 905. CrossRef - Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
Jongwook Yu, Sung Jae Shin, Yune-Jung Park, Hyung Wook Kim, Bo-In Lee, Byong Duk Ye, Geun-Tae Kim, Sung Kook Kim, Joo Sung Kim, Young-Ho Kim, Seonjeong Jeong, Jae Hee Cheon
BMC Gastroenterology.2023;[Epub] CrossRef - Fermented rice bran supplementation attenuates chronic colitis-associated extraintestinal manifestations in female C57BL/6N mice
Jahidul Islam, Afifah Zahra Agista, Kouichi Watanabe, Tomonori Nochi, Hisashi Aso, Yusuke Ohsaki, Takuya Koseki, Michio Komai, Hitoshi Shirakawa
The Journal of Nutritional Biochemistry.2022; 99: 108855. CrossRef - Functional Gastrointestinal Disorders in Patients with Inflammatory Bowel Disease
Kyeong Ok Kim
The Korean Journal of Gastroenterology.2022; 79(1): 4. CrossRef - Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?
Yong Eun Park
Intestinal Research.2022; 20(2): 157. CrossRef - A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease
Kevin Cesa, Catherine Cunningham, Tyler Harris, Whitney Sunseri
Cureus.2022;[Epub] CrossRef - Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim, Dae Ryong Kang
Gut and Liver.2022; 16(4): 555. CrossRef - Medication Adherence in Korean Patients with Inflammatory Bowel
Disease and Its Associated Factors
Kyunghwan Oh, Eun Ja Kwon, Jeong Hye Kim, Kyuwon Kim, Jae Yong Lee, Hee Seung Hong, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jeong Yun Park, Sang Hyoung Park
The Ewha Medical Journal.2022; 45(2): 35. CrossRef - Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef - Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
Intestinal Research.2022; 20(4): 431. CrossRef - A Review of Ophthalmic Complications in Inflammatory Bowel Diseases
Wiktoria Pytrus, Katarzyna Akutko, Tomasz Pytrus, Anna Turno-Kręcicka
Journal of Clinical Medicine.2022; 11(24): 7457. CrossRef - Atopic dermatitis does not increase the risk of inflammatory bowel disease: A nationwide cohort study
Yu‐Ching Weng, Chao‐Kuei Juan, Hsiu J. Ho, Yi‐Ling Chang, Chun‐Ying Wu, Yi‐Ju Chen
The Journal of Dermatology.2021; 48(2): 168. CrossRef - Subclinical sacroiliitis detected by abdominopelvic computed tomography in Korean patients with Crohn’s disease
You-Jung Ha, Hyo Jin Kim, Eugene Lee, Ji Hye Park, Young Soo Park, Yun Jong Lee, Yusuhn Kang, Hyuk Yoon
The Korean Journal of Internal Medicine.2021; 36(4): 868. CrossRef - Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
Jihye Park, Daeun Jeong, Youn Wook Chung, Seunghan Han, Da Hye Kim, Jongwook Yu, Jae Hee Cheon, Ji-Hwan Ryu
Scientific Reports.2021;[Epub] CrossRef - Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management
Gerhard Rogler, Abha Singh, Arthur Kavanaugh, David T. Rubin
Gastroenterology.2021; 161(4): 1118. CrossRef - Pancreatic Associated Manifestations in Pediatric Inflammatory Bowel Diseases
Ugo Cucinotta, Claudio Romano, Valeria Dipasquale
Genes.2021; 12(9): 1372. CrossRef - KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
The Korean Journal of Gastroenterology.2021; 78(2): 105. CrossRef - Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef - Current status of inflammatory bowel diseases in Korea
Suk-Kyun Yang
Journal of the Korean Medical Association.2021; 64(9): 572. CrossRef - A review of ophthalmic manifestations of inflammatory bowel disease and associated treatments
Priya Janardhana, Saad Al-Kadhi
Current Opinion in Ophthalmology.2021; 32(6): 549. CrossRef - Etiopathogenic and Clinical Aspects in Inflammatory Bowel Disease – Literature Review
Petronela Nicoleta Seritean Isac, Diana Popescu, Tudor Marcel Genes, Minerva Codruta Badescu, Ioana Irina Rezus, Nicoleta Dima, Ana Roxana Rusu Ganceanu, Elena Rezus, Ciprian Rezus
Journal of Interdisciplinary Medicine.2021; 6(3): 132. CrossRef - Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef - Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
Intestinal Research.2021; 19(4): 478. CrossRef - Ficus pandurata Hance Inhibits Ulcerative Colitis and Colitis‐Associated Secondary Liver Damage of Mice by Enhancing Antioxidation Activity
Weibo Dai, Xinyi Zhan, Weijie Peng, Xin Liu, Weiwen Peng, Quanxi Mei, Xianjing Hu, Kai Wang
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef - Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders
Stefano Mazza, Sara Soro, Maria Chiara Verga, Biagio Elvo, Francesca Ferretti, Fabrizio Cereatti, Andrea Drago, Roberto Grassia
World Journal of Hepatology.2021; 13(12): 1828. CrossRef - Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease
Istvan Fedor, Eva Zold, Zsolt Barta
Journal of Clinical Medicine.2021; 10(24): 5984. CrossRef
- Pomegranate seed oil mitigates liver and kidney damage in an experimental colitis model: Modulation of NF-κB activation and apoptosis
- 14,938 View
- 444 Download
- 41 Web of Science
- 40 Crossref
Original Articles
- Inflammatory bowel diseases
- Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
- Masayuki Saruta, Dong Il Park, Young-Ho Kim, Suk-Kyun Yang, Byung-Ik Jang, Jae Hee Cheon, Jong Pil Im, Takanori Kanai, Tatsuro Katsuno, Yoh Ishiguro, Makoto Nagaoka, Naoki Isogawa, Yinhua Li, Anindita Banerjee, Alaa Ahmad, Mina Hassan-Zahraee, Robert Clare, Kenneth J. Gorelick, Fabio Cataldi, Mamoru Watanabe, Toshifumi Hibi
- Intest Res 2020;18(1):45-55. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.00039
-
Abstract
PDFPubReaderePub
- Background/Aims
PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7+ lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD).
Methods
OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients.
Results
In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7+ central memory CD4+ T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment.
Conclusions
In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509) -
Citations
Citations to this article as recorded by- Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
Gut and Liver.2023; 17(5): 766. CrossRef - Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
Gut and Liver.2023; 17(6): 905. CrossRef - Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy
Maximilian Wiendl, Emily Becker, Tanja M. Müller, Caroline J. Voskens, Markus F. Neurath, Sebastian Zundler
Frontiers in Immunology.2021;[Epub] CrossRef - Renin–angiotensin system in intestinal inflammation—Angiotensin inhibitors to treat inflammatory bowel diseases?
Hanne Salmenkari, Riitta Korpela, Heikki Vapaatalo
Basic & Clinical Pharmacology & Toxicology.2021; 129(3): 161. CrossRef - Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents
Virginia Solitano, Tommaso Lorenzo Parigi, Elisa Ragaini, Silvio Danese
Expert Opinion on Investigational Drugs.2021; 30(10): 1037. CrossRef - Emerging therapeutic options in inflammatory bowel disease
Jesus K Yamamoto-Furusho, Norma N Parra-Holguín
World Journal of Gastroenterology.2021; 27(48): 8242. CrossRef
- Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
- 15,562 View
- 188 Download
- 7 Web of Science
- 6 Crossref
- Inflammatory bowel diseases
- Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
- Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
- Intest Res 2020;18(1):85-95. Published online July 19, 2019
- DOI: https://doi.org/10.5217/ir.2019.00055
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Patients with inflammatory bowel disease (IBD) are usually hospitalized because of aggravated gastrointestinal symptoms. Many clinicians empirically advise these patients to fast once they are admitted. However, there has been no evidence that maintaining a complete bowel rest improves the disease course. Therefore, we aimed to investigate the effects of fasting on disease course in admitted patients with IBD or intestinal Behçet’s disease.
Methods
A total of 222 patients with IBD or intestinal Behçet’s disease, who were admitted for disease-related symptoms, were retrospectively analyzed. We divided them into 2 groups: fasting group (allowed to take sips of water but no food at the time of admission) and dietary group (received liquid, soft, or general diet).
Results
On admission, 124 patients (55.9%) started fasting and 98 patients (44.1%) started diet immediately. Among patients hospitalized through the emergency room, a significantly higher proportion underwent fasting (63.7% vs. 21.4%, P<0.001); however, 96.0% of the patients experienced dietary changes. Corticosteroid use (P<0.001; hazard ratio, 2.445; 95% confidence interval, 1.506–3.969) was significantly associated with a reduction in the disease activity score, although there was no significant difference between the fasting group and the dietary group in disease activity reduction (P=0.111) on multivariate analysis.
Conclusions
In terms of disease activity reduction, there was no significant difference between the fasting and dietary groups in admitted patients with IBD, suggesting that imprudent fasting is not helpful in improving the disease course. Therefore, peroral diet should not be avoided unless not tolerated by the patient. -
Citations
Citations to this article as recorded by- Outcomes of dietary management approaches in active ulcerative colitis: A systematic review
Abigail Marsh, Sophie Rindfleish, Kalina Bennett, Anthony Croft, Veronique Chachay
Clinical Nutrition.2022; 41(2): 298. CrossRef - Effect of Ramadan intermittent fasting on inflammatory markers, disease severity, depression, and quality of life in patients with inflammatory bowel diseases: A prospective cohort study
Mohamed Negm, Ahmed Bahaa, Ahmed Farrag, Rania M. Lithy, Hedy A. Badary, Mahmoud Essam, Shimaa Kamel, Mohamed Sakr, Waleed Abd El Aaty, Mostafa Shamkh, Ahmed Basiony, Ibrahim Dawoud, Hany Shehab
BMC Gastroenterology.2022;[Epub] CrossRef - Circadian Influences of Diet on the Microbiome and Immunity
Danping Zheng, Karina Ratiner, Eran Elinav
Trends in Immunology.2020; 41(6): 512. CrossRef
- Outcomes of dietary management approaches in active ulcerative colitis: A systematic review
- 13,686 View
- 267 Download
- 4 Web of Science
- 3 Crossref
Brief Communication
- Endoscopy
- Probe-based confocal laser endomicroscopy in the differential diagnosis of inflammatory bowel diseases: a case series
- Jung Won Park, Tae Il Kim, Jae Hee Cheon
- Intest Res 2018;16(4):641-645. Published online October 10, 2018
- DOI: https://doi.org/10.5217/ir.2018.00035
- 5,970 View
- 101 Download
Original Article
- IBD
- Magnetic resonance enterography predicts the prognosis of Crohn's disease
- Ji Hoon Lee, Yong Eun Park, Nieun Seo, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim, Joon Seok Lim, Jae Hee Cheon
- Intest Res 2018;16(3):445-457. Published online July 27, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.3.445
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> Magnetic resonance enterography (MRE) has emerged as an important tool in the diagnosis and follow-up of Crohn's disease (CD). The aim of this study was to evaluate whether MRE findings could predict the prognosis of CD.
Methods In this retrospective study, a total of 173 patients with clinical remission of CD (n=61) or active CD (n=112) were identified. The outcomes of clinical relapse, admission, surgery, and need for other medications according to the MRE findings were evaluated.
Results The presence of active inflammation on MRE was observed in 93 (83%) patients with clinically active CD and in 44 (72.1%) patients with clinical remission of CD, without a statistically significant difference (
P =0.091). In multivariate analysis, active inflammation on MRE increased the risk for clinical relapse (hazard ratio [HR], 6.985; 95% confidence interval [CI], 1.024–47.649) in patients with clinical remission of CD. In patients with clinically active CD, active inflammation on MRE increased the risk for CD-related hospitalization (HR, 2.970; 95% CI, 1.006–8.772).Conclusions The presence of active inflammation on MRE was significantly associated with poor prognosis both in patients with clinical remission of CD and in those with active CD.
-
Citations
Citations to this article as recorded by- The Spectrum of Magnetic Resonance Enterography Findings and the Role of Diffusion-Weighted Imaging in Patients with Active Crohn’s Disease
Arvin Arian, Ghazal Roostaei, Seyede Sahel Rasoulighasemlouei, Foroogh Alborzi Avanaki, Nasser Ebrahimi Daryani
Middle East Journal of Digestive Diseases.2024; 16(1): 23. CrossRef - Distribution of small bowel involvement and its association with clinical outcomes in patients with Crohn’s disease
Jin Park, Hae Young Kim, Yoon Jin Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
Medicine.2023; 102(40): e35040. CrossRef - Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy
Kyunghwan Oh, Eun Hye Oh, Soo Min Noh, Seong Ho Park, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Clinical and Translational Gastroenterology.2022; 13(1): e00442. CrossRef - MR Enterography in Crohnʼs Disease: Comparison of Contrast Imaging with Diffusion-weighted Imaging and a special Form of Color Coding
Maja Jakob, Maik Backes, Christian Schaefer, Joerg Albert, Angela Geissler
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2022; 194(10): 1119. CrossRef - Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef - Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease
Eléonore Hallé, Mustapha Azahaf, Nicolas Duveau, Thomas Lambin, Maria Nachury, Julien Branche, Romain Gérard, Clémentine Lauriot Dit Prevost, Pauline Wils, Pierre Desreumaux, Olivier Ernst, Benjamin Pariente
Digestive Diseases and Sciences.2020; 65(9): 2664. CrossRef - Magnetic Resonance Enterography and Capsule Endoscopy in Patients Undergoing Patency Capsule for the Evaluation of Small Bowel Crohn’s Disease: A Korean Clinical Experience
Hyun Seok Lee, Yun Jeong Lim, Jin-Hee Jung, Ji Hyung Nam, Junseok Park, Sun Hyung Kang, Ki Bae Kim, Hoon Jai Chun
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef - Beyond Crohn Disease
Michael S. Furman, Edward Y. Lee
Radiologic Clinics of North America.2020; 58(3): 517. CrossRef - Mucosal healing in Crohn’s disease: new insights
Salvatore Cucchiara, Giulia D’Arcangelo, Sara Isoldi, Marina Aloi, Laura Stronati
Expert Review of Gastroenterology & Hepatology.2020; 14(5): 335. CrossRef - Changes in the Management of Patients with Crohn’s Disease Based on Magnetic Resonance Enterography Patterns
Evelyn Sayuri S. Chinem, Barbara C. Esberard, Andre da L. Moreira, Tatiana G. Barbassa, Guilherme M. da Cunha, Antonio Jose de V. Carneiro, Heitor S. de Souza, Ana Teresa P. Carvalho
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef
- The Spectrum of Magnetic Resonance Enterography Findings and the Role of Diffusion-Weighted Imaging in Patients with Active Crohn’s Disease
- 7,045 View
- 104 Download
- 9 Web of Science
- 10 Crossref
Brief Communication
- Miscellaneous
- Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience
- Jihye Park, Jae Hee Cheon, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim
- Intest Res 2018;16(2):315-318. Published online April 30, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.2.315
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by- Behçet's syndrome
Giacomo Emmi, Alessandra Bettiol, Gülen Hatemi, Domenico Prisco
The Lancet.2024; 403(10431): 1093. CrossRef - Current pharmacological solutions for Behçet’s syndrome
Yesim Ozguler, Sinem Nihal Esatoglu, Gulen Hatemi
Expert Opinion on Pharmacotherapy.2023; 24(2): 221. CrossRef - Treatment Options in Pediatric Behçet’s Disease
Teresa Giani, Angela Flavia Luppino, Giovanna Ferrara
Pediatric Drugs.2023; 25(2): 165. CrossRef - Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef - Long-term outcome and predictors of remission in Behçet’s disease in daily practice
Aida Malek Mahdavi, Alireza Khabbazi, Mehrzad Hajialilo
Modern Rheumatology.2021; 31(6): 1148. CrossRef - Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
Da Hye Kim, Soochan Kim, Jae Bum Ahn, Jae Hyeon Kim, Hyun Woo Ma, Dong Hyuk Seo, Xiumei Che, Ki Cheong Park, Jeong Yong Jeon, Sang Yong Kim, Han Cheol Lee, Jae-Young Lee, Tae Il Kim, Won Ho Kim, Seung Won Kim, Jae Hee Cheon
International Journal of Medical Microbiology.2020; 310(2): 151391. CrossRef - Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet’s disease
H. J. Kim, K.‑t. Kim, S.-G. Lee, Y. Kim
Zeitschrift für Rheumatologie.2020; 79(7): 702. CrossRef - Safety of systemic treatments for Behçet’s syndrome
Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini, Florenzo Iannone
Expert Opinion on Drug Safety.2020; 19(10): 1269. CrossRef - Update on the treatment of Behçet’s syndrome
Sinem Nihal Esatoglu, Gulen Hatemi
Internal and Emergency Medicine.2019; 14(5): 661. CrossRef
- Behçet's syndrome
- 5,098 View
- 68 Download
- 8 Web of Science
- 9 Crossref
Focused Review: Intestinal Behçet's Disease
- Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease
- Hyun Jung Lee, Jae Hee Cheon
- Intest Res 2017;15(3):311-317. Published online June 12, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.3.311
-
Abstract
PDFPubReaderePub
Intestinal Behçet's disease (BD), generally accepted as a type of inflammatory bowel disease (IBD), could be diagnosed when patients with BD have objectively documented gastrointestinal symptoms and intestinal ulcerations. Similar to IBD, intestinal BD has an unpredictable disease course with relapse and remission and is often related to a poor prognosis. However, there is no single gold standard for assessment of the disease activity of intestinal BD, and its diagnosis and management depend heavily on expert opinions. The Korean IBD Study Group recently developed novel diagnostic criteria based on colonoscopy findings and clinical manifestations using a modified Delphi process to overcome drawbacks of previously used consensus for the diagnosis of intestinal BD. In addition, the recently developed disease activity index for intestinal BD, consisting of a relatively simple 8-point index, could also help in determining treatment strategies and monitoring therapeutic responses. In this review, the progress in the diagnosis and disease activity measurement of intestinal BD will be discussed.
-
Citations
Citations to this article as recorded by- Predicting Factors of Long-term Outcome of Gastrointestinal Behçet's Disease: A Chinese Retrospective Study
Xiaoman Zu, Shanshan Xiong, Yaming Lu, Ning Zhang, Shu Xu, Rui Feng, Baili Chen, Zhirong Zeng, Minhu Chen, Yao He
Clinical Therapeutics.2024; 46(3): 201. CrossRef - Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
European Journal of Gastroenterology & Hepatology.2024; 36(4): 445. CrossRef - Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients
Ga Hee Kim, Minjun Kim, Kyuwon Kim, Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Yonsei Medical Journal.2024; 65(5): 276. CrossRef - Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study
Jung-Bin Park, So Jung Han, Seung Bum Lee, Dong Hyun Kim, Jae Hee Cheon, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Soo Jung Park, Sang Hyoung Park
Yonsei Medical Journal.2024; 65(5): 265. CrossRef - Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet’s Disease: A Systematic Review and Meta-Analysis
Qingfeng Zhang, Chunyan Ma, Rongrong Dong, Weizhen Xiang, Meiqi Li, Zhenzhen Ma, Qingrui Yang
Yonsei Medical Journal.2022; 63(2): 148. CrossRef - Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet’s disease: Case report and the review of literature
Takashi Onaka, Kazuhisa Nakano, Yuri Uemoto, Naoto Miyakawa, Yasuyuki Otsuka, Aiko Ogura-Kato, Fumie Iwai, Yoshiya Tanaka, Akihito Yonezawa
Modern Rheumatology Case Reports.2022; 6(2): 273. CrossRef - 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behcet’s Disease
Burak İnce, Ali Kibar, Sertaç Asa, Rabia Lebriz Uslu Beşli, Muhammet Sait Sağer, Ahmet Emre Eşkazan, Ali İbrahim Hatemi, Gülen Hatemi, Kerim Sönmezoğlu
Molecular Imaging and Radionuclide Therapy.2022; 31(1): 57. CrossRef - Clinical Course of Patients with Intestinal Behçet’s Disease According to Consensus-Based Diagnostic Categories
Yu Young Joo, Bo-In Lee, Seung-Jun Kim, Han Hee Lee, Jin Su Kim, Jae Myung Park, Young-Seok Cho, Kang Moon Lee, Sang Woo Kim, Hwang Choi, Myung-Gyu Choi
Gut and Liver.2022; 16(5): 746. CrossRef - Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet’s Disease with Intestinal Involvement and Crohn’s Disease
Fatma Alibaz-Oner, Rabia Ergelen, Ilkay Ergenc, Gizem Seven, Ayten Yazıcı, Ayse Cefle, Cemal Bes, Ozlen Atug, Haner Direskeneli
Digestive Diseases and Sciences.2021; 66(8): 2750. CrossRef - Deep‐learning system for real‐time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis
Jung Min Kim, Jun Gu Kang, Sungwon Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2021; 36(8): 2141. CrossRef - Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
Jihye Park, Daeun Jeong, Youn Wook Chung, Seunghan Han, Da Hye Kim, Jongwook Yu, Jae Hee Cheon, Ji-Hwan Ryu
Scientific Reports.2021;[Epub] CrossRef - Behçet syndrome
Yusuf Yazici, Gulen Hatemi, Bahram Bodaghi, Jae Hee Cheon, Noburu Suzuki, Nicola Ambrose, Hasan Yazici
Nature Reviews Disease Primers.2021;[Epub] CrossRef - C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet’s disease
Eun Ae Kang, Jung Won Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Min Soo Cho, Jae Hee Cheon
BMC Gastroenterology.2021;[Epub] CrossRef - Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents
Yehyun Park, Jae Hee Cheon
Current Gastroenterology Reports.2020;[Epub] CrossRef - A20 Haploinsufficiency in a Chinese Patient With Intestinal Behcet's Disease-Like Symptoms: A Case Report
Yu Chen, Huanjun Huang, Yao He, Minhu Chen, Ursula Seidler, De'an Tian, Fang Xiao
Frontiers in Immunology.2020;[Epub] CrossRef - Association of Clinical Phenotypes in Haploinsufficiency A20 (HA20) With Disrupted Domains of A20
Yu Chen, Zhenghao Ye, Liping Chen, Tingting Qin, Ursula Seidler, De'an Tian, Fang Xiao
Frontiers in Immunology.2020;[Epub] CrossRef - Behсet's disease: intestinal damage
R. G. Goloeva, Z. S. Alekberova
Rheumatology Science and Practice.2019; 56(6): 767. CrossRef - Successful closure of ileostomy in a patient with intestinal Behçet's disease after therapy with adalimumab
Zhe Yan, Bei-Bei Cui, Yong-Yang Yu, Geng Yin, Xiao-Min Cen, Qi-Bing Xie
Medicine.2019; 98(9): e14624. CrossRef - Intestinal manifestations of Behçet's disease
R G Goloeva, Z S Alekberova, T A Lisitsyna, E A Stepanova, L P Orlova
Terapevticheskii arkhiv.2019; 91(5): 111. CrossRef - Cancer Risk in Patients with Intestinal Behçet’s Disease: A Nationwide Population-Based Study
Minkyung Han, Yoon Suk Jung, Won Ho Kim, Jae Hee Cheon, Sohee Park
Gut and Liver.2018; 12(4): 433. CrossRef - Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef
- Predicting Factors of Long-term Outcome of Gastrointestinal Behçet's Disease: A Chinese Retrospective Study
- 8,948 View
- 185 Download
- 20 Web of Science
- 21 Crossref
Editorial
- Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
- Jihye Park, Jae Hee Cheon
- Intest Res 2017;15(3):263-265. Published online June 12, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.3.263
- 4,500 View
- 44 Download
- 2 Web of Science
- 2 Crossref
Original Articles
- Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease
- Hui Won Jang, Hyun Sook Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
- Intest Res 2016;14(4):305-313. Published online October 17, 2016
- DOI: https://doi.org/10.5217/ir.2016.14.4.305
-
Abstract
PDFPubReader
<b>Background/Aims</b><br/> Several studies have found that the measurement of fecal calprotectin is useful for the early diagnosis of inflammatory bowel disease (IBD). We compared the effectiveness of three different fecal calprotectin kits for initial diagnosis in patients with suspected IBD.
Methods We enrolled 31 patients with IBD (18 Crohn's disease [CD], 11 ulcerative colitis [UC], and two intestinal Behçet's disease), five with irritable bowel syndrome (IBS), and five with other colitis (four infectious colitis and one intestinal tuberculosis). Diagnosis was based on clinical, laboratory, and endoscopic examinations. Fecal samples were obtained at the first diagnosis and calprotectin levels were measured using three different kits (Quantum Blue® Calprotectin, EliA™ Calprotectin, and RIDASCREEN® Calprotectin).
Results The overall accuracy for differentiating IBD from IBS or other colitis was 94% and 91%, respectively, for Quantum Blue® (cutoff, 50 µg/g); 92% and 89%, respectively, for EliA™ (cutoff, 50 µg/g); and 82% and 76%, respectively, for RIDASCREEN® (cutoff, 50 µg/g). In patients with CD, the results of Quantum Blue® Calprotectin and EliA™ Calprotectin correlated significantly with levels of the Crohn's disease activity index (Spearman's rank correlation coefficient, r=0.66 and r=0.49, respectively). In patients with UC, the results of EliA™ Calprotectin correlated significantly with the Mayo score (r=0.70).
Conclusions Fecal calprotectin measurement is useful for the identification of IBD. The overall accuracies of the three fecal calprotectin kits are comparable.
-
Citations
Citations to this article as recorded by- Values of serum intestinal fatty acid-binding protein, fecal calprotectin, and fecal human β-defensin 2 for predicting necrotizing enterocolitis
Sujia Liu, Yongle Liu, Shuhua Lai, Yingling Xie, Wenlong Xiu, Changyi Yang
BMC Pediatrics.2024;[Epub] CrossRef - Multimodal Ultrasound Technology Combined with Fecal Calprotectin Assessment in Clinical Studies of Inflammatory Bowel Disease
泊辛 陈
Advances in Clinical Medicine.2024; 14(07): 1110. CrossRef - The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
Intestinal Research.2021; 19(1): 62. CrossRef - The utility of faecal and urine biomarkers for small bowel diseases
M.S. Ismail, Serhiy Semenov, Deirdre McNamara
Current Opinion in Gastroenterology.2021; 37(3): 284. CrossRef - A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease
Jong-Mi Lee, Joo Hee Jang, Ji Hyeong Ryu, Jaeeun Yoo, Bo-In Lee, Seung-Jun Kim, Eun-Jee Oh, Hsu-Heng Yen
PLOS ONE.2021; 16(8): e0255974. CrossRef - Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis
Ho Min Yong, Sung-Jo Park, Seong Ran Jeon, Heesu Park, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Hyeon Jeong Goong, Suyeon Park
Medicine.2021; 100(34): e27065. CrossRef - Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn’s Disease Based on Serum Levels of Proteins
Geert D’Haens, Orlaith Kelly, Robert Battat, Mark S. Silverberg, David Laharie, Edouard Louis, Edoardo Savarino, Giorgia Bodini, Andres Yarur, Brigid S. Boland, Waqqas Afif, Xiao-jun Li, Michael Hale, Jessica Ho, Venkateswarlu Kondragunta, Benjamin Huang,
Gastroenterology.2020; 158(3): 515. CrossRef - Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations
Emilio J. Laserna-Mendieta, Alfredo J. Lucendo
Clinical Chemistry and Laboratory Medicine (CCLM).2019; 57(9): 1295. CrossRef - Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?
Christopher Ma, Robert Battat, Claire E. Parker, Reena Khanna, Vipul Jairath, Brian Gordon Feagan
Expert Review of Gastroenterology & Hepatology.2019; 13(4): 319. CrossRef - Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
Parambir S. Dulai, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E. Sands, Axel Dignass, Dan Turner, Gerassimos Mantzaris, Juergen Schölmerich, Jean-Yves Mary, Walter Reinisch, William J. Sandborn
Gastroenterology.2019; 157(4): 1032. CrossRef - Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy
Karoline Freeman, Brian H Willis, Hannah Fraser, Sian Taylor-Phillips, Aileen Clarke
BMJ Open.2019; 9(3): e027428. CrossRef - Extraction, isolation, and concentration of calprotectin antigen (S100A8/S100A9) from granulocytes
Tom Nilsen, Siri Helen Haugen, Anders Larsson
Health Science Reports.2018;[Epub] CrossRef - Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis
Ji Young Chang, Jae Hee Cheon
Gut and Liver.2018; 12(2): 117. CrossRef - Fecal calprotectin is not superior to serum C-reactive protein or the Harvey–Bradshaw index in predicting postoperative endoscopic recurrence in Crohn’s disease
Cristina Verdejo, Daniel Hervías, Óscar Roncero, Ángel Arias, Abdelmouneim Bouhmidi, Rufo Lorente, Irina Salueña, Alfredo J. Lucendo
European Journal of Gastroenterology & Hepatology.2018; 30(12): 1521. CrossRef - Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring
Shu-Chen Wei, Chien-Chih Tung, Meng-Tzu Weng, Jau-Min Wong
Intestinal Research.2018; 16(4): 546. CrossRef - Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
The American Journal of the Medical Sciences.2017; 353(5): 439. CrossRef - Fecal biomarkers in inflammatory bowel disease: how, when and why?
Paula Ministro, Diana Martins
Expert Review of Gastroenterology & Hepatology.2017; 11(4): 317. CrossRef - Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?
Shu Chen Wei
Intestinal Research.2016; 14(4): 293. CrossRef
- Values of serum intestinal fatty acid-binding protein, fecal calprotectin, and fecal human β-defensin 2 for predicting necrotizing enterocolitis
- 6,650 View
- 67 Download
- 17 Web of Science
- 18 Crossref
- Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study
- Sinyoung Park, Yang Hee Noh, Sun Young Rha, Won Ho Kim, Jae Hee Cheon
- Intest Res 2015;13(3):274-281. Published online June 9, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.3.274
-
Abstract
PDFPubReader
<b>Background/Aims</b><br/> The growing volume and the diversity of clinical research has led to related laws and regulations as well as the Institutional Review Board (IRB) approval process becoming more stringent. To conduct clinical research efficiently and while following regulations, information about the IRB approval process and feedback is important for investigators. This has yet to be studied.
Methods We included 381 gastrointestinal disease research proposals (79 with inflammatory bowel disease [IBD], and 302 with non-IBD) reviewed by the IRB of Severance Hospital between January 2009 and December 2013. We retrospectively analyzed research characteristics including research risk levels, results of initial reviews, frequencies of continuing review, numbers of IRB comments, frequencies of IRB comments, and durations from submission to approval.
Results Investigators' decisions on risk level were higher in the IBD group than in the non-IBD group (
P <0.05). Results of initial reviews, frequencies of continuing reviews, the numbers of IRB review comments, and durations from submission to approval were not different between the two groups, but IRB decisions on risk level were higher in the IBD group (P <0.05). In subgroup analysis, the number of IRB comments from initial review on informed consent forms and procedures as well were quest of more information were significantly higher in the IBD group than in the non-IBD group (P <0.001 and 0.01, respectively).Conclusions In Korea, rare diseases such as IBD require more information for the IRB process due to their distinct characteristics. IBD researchers should develop research protocols more carefully and make their research as subject-friendly as possible.
-
Citations
Citations to this article as recorded by- Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management
Jihye Park, Sinyoung Park, Shin Ae Lee, Soo Jung Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2021; 36(5): 1040. CrossRef - Evaluation of Serious Adverse Event Reporting Forms for Clinical Trials: A Comparative Korean Study
Heeyoung Lee, Cholong Park, Jinwon Choi, Seongeun Jeong, Hyunin Cho, Wooseong Huh, Eunyoung Kim
Journal of Empirical Research on Human Research Ethics.2020; 15(5): 415. CrossRef - ‘Screening audit’ as a quality assurance tool in good clinical practice compliant research environments
Sinyoung Park, Chung Mo Nam, Sejung Park, Yang Hee Noh, Cho Rong Ahn, Wan Sun Yu, Bo Kyung Kim, Seung Min Kim, Jin Seok Kim, Sun Young Rha
BMC Medical Ethics.2018;[Epub] CrossRef
- Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management
- 5,963 View
- 54 Download
- 3 Web of Science
- 3 Crossref
Special Review
- Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future
- Jung Won Lee, Jong Pil Im, Jae Hee Cheon, You Sun Kim, Joo Sung Kim, Dong Soo Han
- Intest Res 2015;13(3):213-218. Published online June 9, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.3.213
-
Abstract
PDFPubReader
Inflammatory bowel disease (IBD) is defined as a chronic and relapsing inflammatory disorder of the intestine. Intestinal inflammation in IBD has been proposed to be attributable to the interplay between microbial, genetic, environmental, and immunological factors. The incidence and prevalence rates of IBD are rapidly increasing apparently in other parts of the world, with dramatic increases especially in East Asia. Generally, cohort studies are useful for estimating the incidence, prevalence, natural course, prognosis, and risk factors of diseases. In particular, cohort studies performed in Western countries have well described the prevalence, risk factors, and natural course of IBD and investigated its genetic pathophysiology. However, the outcomes of IBD cohort studies performed in Korea are not as persuasive as those of Western studies because of the relatively low prevalence of IBD and short follow-up periods of the cohorts in Korea. Despite this critical limitation, members of the Korean Association for the Study of Intestinal Diseases have demonstrated outstanding results. Some unique features of IBD patients in Korea are well demonstrated, such as thiopurine-induced leukopenia or risks of opportunistic tuberculosis infection in patients receiving tumor necrosis factor-α inhibitors. In this review, the present authors summarized the key points of the results of the cohort studies performed in Korea and explored future perspectives.
-
Citations
Citations to this article as recorded by- CXCL10 as a shared specific marker in rheumatoid arthritis and inflammatory bowel disease and a clue involved in the mechanism of intestinal flora in rheumatoid arthritis
Yin Guan, Yue Zhang, Yifan Zhu, Yue Wang
Scientific Reports.2023;[Epub] CrossRef - Plasma miRNA Profile of Crohn’s Disease and Rheumatoid Arthritis Patients
Tatiana D. Saccon, Joseph M. Dhahbi, Augusto Schneider, Yury O. Nunez Lopez, Ahmad Qasem, Marcelo B. Cavalcante, Lauren K. Sing, Saleh A. Naser, Michal M. Masternak
Biology.2022; 11(4): 508. CrossRef - Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef - Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park
JMIR Medical Informatics.2020; 8(4): e15124. CrossRef - Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database
Jiyool Kim, So-Hee Park, Ju-Young Shin
Korean Journal of Clinical Pharmacy.2020; 30(2): 102. CrossRef - Association study between two polymorphisms of tumor necrosis factor ligand superfamily member 15 (TNFSF15) gene and ulcerative colitis in south‐west of Iran
Marzieh Taheri, Pegah Ghandil, Seyyed Jalal Hashemi, Mehri Ghafourian, Abdol Rahim Masjedi Zadeh, Ata Allah Ghadiri
Journal of Cellular Biochemistry.2019; 120(5): 8784. CrossRef - A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis
in Korea (MOSAIK) cohort study
Chang Kyun Lee, Kang-Moon Lee, Dong Il Park, Sung-Ae Jung, Yoon Tae Jeen, Young Sook Park, Hyo Jong Kim
Intestinal Research.2019; 17(1): 1. CrossRef - Dermatologic Manifestations in Inflammatory Bowel Disease
Hyun Yi Suh, Woo Jin Lee, Soo-Young Na
The Korean Journal of Gastroenterology.2019; 73(5): 285. CrossRef - Depressive Symptoms and Quality of Life in the Patients of Inflammatory Bowel Disease
Jung Won Lee
Gut and Liver.2017; 11(4): 449. CrossRef - Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: A nationwide population-based study
Jung Min Bae, Ji Yoon Choo, Ki-Jo Kim, Kyung-Su Park
Modern Rheumatology.2017; 27(3): 435. CrossRef - Ophthalmologic manifestations in patients with inflammatory bowel disease
Hye Jin Lee, Hyun Joo Song, Jin Ho Jeong, Heung Up Kim, Sun-Jin Boo, Soo-Young Na
Intestinal Research.2017; 15(3): 380. CrossRef - Hydrogen-rich water protects against inflammatory bowel disease in mice by inhibiting endoplasmic reticulum stress and promoting heme oxygenase-1 expression
Nai-Ying Shen, Jian-Bin Bi, Jing-Yao Zhang, Si-Min Zhang, Jing-Xian Gu, Kai Qu, Chang Liu
World Journal of Gastroenterology.2017; 23(8): 1375. CrossRef - Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
Young Sun Kim, Sung-Ae Jung, Kang-Moon Lee, Soo Jung Park, Tae Oh Kim, Chang Hwan Choi, Hyun Gun Kim, Won Moon, Chang Mo Moon, Hye Kyoung Song, Soo-Young Na, Suk-Kyun Yang
Intestinal Research.2017; 15(3): 338. CrossRef - Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study
Jee Hye Kwon, Jong Pil Im, Byong Duk Ye, Jae Hee Cheon, Hyun Joo Jang, Kang Moon Lee, You Sun Kim, Sang Wook Kim, Young Ho Kim, Geun Am Song, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2016; 10(4): 595. CrossRef - Crohn's disease confined to the duodenum: A case report
Dong Jin Song, Il Soon Whang, Hyung Wook Choi, Cheol Yun Jeong, Sung Hoon Jung
World Journal of Clinical Cases.2016; 4(6): 146. CrossRef - Importance of Patients’ Knowledge of Their Prescribed Medication in Improving Treatment Adherence in Inflammatory Bowel Disease
Chung Hyun Tae, Sung-Ae Jung, Hye Sung Moon, Jung-A Seo, Hye Kyung Song, Chang Mo Moon, Seong-Eun Kim, Ki-Nam Shim, Hye-Kyung Jung
Journal of Clinical Gastroenterology.2016; 50(2): 157. CrossRef - Fusobacterium Isolates Recovered From Colonic Biopsies of Inflammatory Bowel Disease Patients in Korea
Yangsoon Lee, Chang Soo Eun, A Reum Lee, Chan Hyuk Park, Dong Soo Han
Annals of Laboratory Medicine.2016; 36(4): 387. CrossRef - Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study
Bun Kim, Jae Hee Cheon, Hyun Jin Moon, Yi Rang Park, Byong Duk Ye, Suk‐Kyun Yang, Geom Seog Seo, Byung Ik Jang, You Sun Kim, Joo Sung Kim, Dong Soo Han, Young‐Ho Kim, Won Ho Kim
Journal of Gastroenterology and Hepatology.2016; 31(1): 126. CrossRef
- CXCL10 as a shared specific marker in rheumatoid arthritis and inflammatory bowel disease and a clue involved in the mechanism of intestinal flora in rheumatoid arthritis
- 6,069 View
- 55 Download
- 17 Web of Science
- 18 Crossref
Editorial
- A Clinical Significance of Assessing Cytomegalovirus Infection Status in Patients With Ulcerative Colitis
- Sooyun Chang, Jae Hee Cheon
- Intest Res 2015;13(1):2-3. Published online January 29, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.1.2
-
PDFPubReader
-
Citations
Citations to this article as recorded by- A quick guide to diagnosis and treatment of cytomegalovirus infection in the gut: current dilemmas
Iļja Drjagunovs, Sniedze Laivacuma, Indra Zeltiņa, Aleksejs Derovs
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences..2022; 76(5-6): 585. CrossRef - Approach to cytomegalovirus infections in patients with ulcerative colitis
Sung Chul Park, Yoon Mi Jeen, Yoon Tae Jeen
The Korean Journal of Internal Medicine.2017; 32(3): 383. CrossRef - Author's Reply
Jaeyoung Chun, Jong Pil Im
Intestinal Research.2015; 13(2): 184. CrossRef
- A quick guide to diagnosis and treatment of cytomegalovirus infection in the gut: current dilemmas
- 3,794 View
- 52 Download
- 3 Web of Science
- 3 Crossref
Commentary
- Crohn's Disease Clinical Network and Cohort (CONNECT) Study: The First Step Toward Nationwide Multicenter Research of Crohn's Disease in Korea
- Jae Hee Cheon, You Sun Kim, Byong Duk Ye, Kang Moon Lee, Young Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
- Intest Res 2014;12(3):173-175. Published online July 25, 2014
- DOI: https://doi.org/10.5217/ir.2014.12.3.173
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by- Modern treatment of perianal fistulas following Crohn’s disease
A.L. Bejanyan, A.A. Bumbazhai, K.N. Petrenko, A.A. Sumbaev, A.V. Matinyan, I.I. Eremin
Regenerative biotechnologies, preventive, digital and predictive medicine.2024; 1(2): 49. CrossRef - Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef - Clinical Characteristics of Korean Patients with Elderly-Onset Crohn’s Disease: Results from the Prospective CONNECT Study
You Sun Kim, Min Jeong Na, Byong Duk Ye, Jae Hee Cheon, Jong Pil Im, Joo Sung Kim
Gut and Liver.2022; 16(6): 995. CrossRef - Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
Gut and Liver.2022; 16(6): 907. CrossRef - Treatment Strategy for Perianal Fistulas in Crohn Disease Patients: The Surgeon’s Point of View
Jong Lyul Lee, Yong Sik Yoon, Chang Sik Yu
Annals of Coloproctology.2021; 37(1): 5. CrossRef - Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef - Clinical Features of Intra-Abdominal Abscess and Intestinal Free-Wall Perforation in Korean Patients with Crohn’s Disease: Results from the CONNECT Study
Seok-Hoo Jeong, Ja Sung Choi, Jin Woo Kim, Hee Man Kim, Hyun-Soo Kim, Jong Pil Im, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Won Ho Kim, Byong Duk Ye, Young-Ho Kim, Dong Soo Han
Journal of Clinical Medicine.2020; 10(1): 116. CrossRef - Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East
Masoud M Malekzadeh, Alireza Sima, Sudabeh Alatab, Anahita Sadeghi, Nasser Ebrahimi Daryani, Payman Adibi, Iradj Maleki, Hassan Vossoughinia, Hafez Fakheri, Abbas Yazdanbod, Seyed Alireza Taghavi, Rahim Aghazadeh, Mohammad Hassan Somi, Kazem Zendedel, Hom
Intestinal Research.2019; 17(3): 330. CrossRef - Postoperative course of Crohn disease according to timing of bowel resection
Ji Min Lee, Kang-Moon Lee, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, Dong Soo Han, Chang Kyun Lee, Hyun-Ju Park
Medicine.2018; 97(16): e0459. CrossRef - Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2018; 12(5): 544. CrossRef - Second Korean Guidelines for the Management of Crohn's Disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
The Korean Journal of Gastroenterology.2017; 69(1): 29. CrossRef - Second Korean guidelines for the management of Crohn's disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
Intestinal Research.2017; 15(1): 38. CrossRef - Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
The American Journal of the Medical Sciences.2017; 353(5): 439. CrossRef - A coding variant inFTOconfers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD
Han Sang Kim, Jae Hee Cheon, Eun Suk Jung, Joonhee Park, Sowon Aum, Soo Jung Park, Sungho Eun, Jinu Lee, Ulrich Rüther, Giles S H Yeo, Marcella Ma, Kyong Soo Park, Takeo Naito, Yoichi Kakuta, Ji Hyun Lee, Won Ho Kim, Min Goo Lee
Gut.2017; 66(11): 1926. CrossRef - Development of a Novel Predictive Model for the Clinical Course of Crohnʼs Disease
Yehyun Park, Jae Hee Cheon, Yi Lang Park, Byong Duk Ye, You Sun Kim, Dong Soo Han, Joo Sung Kim, Sung Noh Hong, Young Ho Kim, Seong Ran Jeon, Won Ho Kim
Inflammatory Bowel Diseases.2017; 23(7): 1071. CrossRef - Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: Results from the CONNECT study
Sung Wook Hwang, Jee Hyun Kim, Jong Pil Im, Byong Duk Ye, Hoon Sup Koo, Kyu Chan Huh, Jae Hee Cheon, You Sun Kim, Young Ho Kim, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Journal of Gastroenterology and Hepatology.2017; 32(10): 1716. CrossRef - Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study
Bun Kim, Jae Hee Cheon, Hyun Jin Moon, Yi Rang Park, Byong Duk Ye, Suk‐Kyun Yang, Geom Seog Seo, Byung Ik Jang, You Sun Kim, Joo Sung Kim, Dong Soo Han, Young‐Ho Kim, Won Ho Kim
Journal of Gastroenterology and Hepatology.2016; 31(1): 126. CrossRef - Deep resequencing of 131 Crohn's disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants
Sung Noh Hong, Changho Park, Soo Jung Park, Chang Kyun Lee, Byong Duk Ye, You Sun Kim, Seungbok Lee, Jeesoo Chae, Jong-Il Kim, Young-Ho Kim
Gut.2016; 65(5): 788. CrossRef - Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study
Jee Hye Kwon, Jong Pil Im, Byong Duk Ye, Jae Hee Cheon, Hyun Joo Jang, Kang Moon Lee, You Sun Kim, Sang Wook Kim, Young Ho Kim, Geun Am Song, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2016; 10(4): 595. CrossRef - The clinical characteristics of patients with free perforation in Korean Crohn’s disease: results from the CONNECT study
Young Seok Doh, You Sun Kim, Song I Bae, Jong Pil Im, Jae Hee Cheon, Byong Duk Ye, Ji Won Kim, Young Sook Park, Ji Hyun Lee, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
BMC Gastroenterology.2015;[Epub] CrossRef - Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn’s Disease Patients: Results from the CONNECT Study
Chang Mo Moon, Sung-Ae Jung, Seong-Eun Kim, Hyun Joo Song, Yunho Jung, Byong Duk Ye, Jae Hee Cheon, You Sun Kim, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Mathias Chamaillard
PLOS ONE.2015; 10(12): e0144390. CrossRef - Long-term Clinical Outcomes of Urban Versus Rural Environment in Korean Patients with Crohn's Disease: Results from the CONNECT Study
Y. S. Jung, D. I. Park, B. D. Ye, J. H. Cheon, Y. S. Kim, Y. H. Kim, J. S. Kim, H. S. Chae, G. H. Baik, D. S. Han
Journal of Crohn's and Colitis.2015; 9(3): 246. CrossRef - Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future
Jung Won Lee, Jong Pil Im, Jae Hee Cheon, You Sun Kim, Joo Sung Kim, Dong Soo Han
Intestinal Research.2015; 13(3): 213. CrossRef - Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study
Sinyoung Park, Yang Hee Noh, Sun Young Rha, Won Ho Kim, Jae Hee Cheon
Intestinal Research.2015; 13(3): 274. CrossRef - Crohn's disease in Korea: past, present, and future
Kang-Moon Lee, Ji Min Lee
The Korean Journal of Internal Medicine.2014; 29(5): 558. CrossRef
- Modern treatment of perianal fistulas following Crohn’s disease
- 6,297 View
- 73 Download
- 23 Web of Science
- 25 Crossref
Original Article
- Vaccination and Complementary and Alternative Medicine in Patients with Inflammatory Bowel Disease
- Sung Bae Kim, Soo Jung Park, Sook Hee Chung, Kyu Yeon Hahn, Do Chang Moon, Sung Pil Hong, Jae Hee Cheon, Tae Il Kim, Won Ho Kim
- Intest Res 2014;12(2):124-130. Published online April 29, 2014
- DOI: https://doi.org/10.5217/ir.2014.12.2.124
-
Abstract
PDFPubReader
<b>Background/Aims</b><br/> Vaccinations in patients with inflammatory bowel disease (IBD) are recommended to prevent infectious diseases. However, there are few reports of vaccination in IBD patients in Korea. The frequency of complementary and alternative medicine (CAM) use is high despite its uncertain effectiveness. This study aimed to identify the rates of vaccination and use of CAM in patients with IBD.
Methods A total of 219 patients attended an education session for IBD patients held at Severance Hospital on March 23, 2013. We conducted a survey on vaccination and CAM use in IBD patients; 120 patients completed the questionnaire.
Results The influenza vaccination rate was 44.2% and pneumococcal vaccination rate was 4.2%. Thirty-one (66%) patients were aware of the importance of vaccination. The vaccination rate was higher in patients who were aware of the importance of vaccination compared with that in patients who were unaware of the importance of vaccination (70.1% vs. 41.7%,
P =0.004). The rate of CAM use was 30.0%. The most commonly used CAMs were oral products: vitamins (33.3%), red ginseng (25.0%), and probiotics (19.4%).Conclusions Awareness of the importance of vaccination and actual vaccination rates were low in IBD patients. Despite insufficient evidence on the effectiveness of CAMs in IBD patients, many patients used CAMs. We believe that repeated education and promotion of vaccination are important. Further large-scale studies to investigate the efficacy and safety of CAMs are warranted in patients with IBD.
-
Citations
Citations to this article as recorded by- Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
Joo Kyung Kim, Jae Hee Cheon
Journal of Yeungnam Medical Science.2023; 40(1): 37. CrossRef - Adherence to Recommended Immunization Schedules in Patients with Inflammatory Bowel Disease on Biologics and Small Molecule Therapies
Mohammad Shehab, Ranim Almatar, Rawan Almohammad, Ahmad Alfadhli
Gastroenterology Insights.2023; 14(3): 383. CrossRef - SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
Intestinal Research.2022; 20(2): 171. CrossRef - Vaccinations and inflammatory bowel disease – a systematic review
Webber Chan, Ennaliza Salazar, Teong Guan Lim, Wan Chee Ong, Hang Hock Shim
Digestive and Liver Disease.2021; 53(9): 1079. CrossRef - SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID
Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
The Korean Journal of Gastroenterology.2021; 78(2): 117. CrossRef - A recent update on the use of Chinese medicine in the treatment of inflammatory bowel disease
Lin Yang, Hua Luo, Dechao Tan, Siyuan Zhang, Zhangfeng Zhong, Shengpeng Wang, Chi Teng Vong, Yitao Wang
Phytomedicine.2021; 92: 153709. CrossRef - Insufficient vaccination and inadequate immunization rates among Korean patients with inflammatory bowel diseases
Han Hee Ryu, Kiju Chang, Nayoung Kim, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Medicine.2021; 100(45): e27714. CrossRef - Complementary and alternative medicine in patients with inflammatory bowel disease: hype or evidence?
Jae Myung Cha
Intestinal Research.2020; 18(2): 141. CrossRef - Complementary and Alternative Medicine Use in Children With Inflammatory Bowel Disease
Uma P. Phatak, Arik Alper, Dinesh S. Pashankar
Journal of Pediatric Gastroenterology and Nutrition.2019; 68(2): 157. CrossRef - Prevalence and indicators of use of complementary and alternative medicine in Austrian patients with inflammatory bowel disease
Hans Peter Gröchenig, Thomas Waldhör, Thomas Haas, Heimo Wenzl, Pius Steiner, Robert Koch, Thomas Feichtenschlager, Gerald Eckhardt, Andreas Mayer, Andreas Kirchgatterer, Othmar Ludwiczek, Reingard Platzer, Pavol Papay, Johanna Gartner, Harry Fuchssteiner
European Journal of Gastroenterology & Hepatology.2019; 31(10): 1211. CrossRef - The who-when-why triangle of complementary and alternative medicine use among Portuguese IBD patients
Francisco Portela, Camila C. Dias, Paulo Caldeira, Marilia Cravo, João Deus, Raquel Gonçalves, Paula Lago, Henrique Morna, Paula Peixe, Jaime Ramos, Helena Sousa, Lurdes Tavares, Helena Vasconcelos, Fernando Magro, Paula Ministro
Digestive and Liver Disease.2017; 49(4): 388. CrossRef - Chlorogenic acid suppresses lipopolysaccharide-induced nitric oxide and interleukin-1β expression by inhibiting JAK2/STAT3 activation in RAW264.7 cells
Sang-Hun Kim, Sun-Young Park, Young-Lan Park, Dae-Seong Myung, Jong-Sun Rew, Young-Eun Joo
Molecular Medicine Reports.2017; 16(6): 9224. CrossRef - Vaccination in Inflammatory Bowel Disease Patients: Attitudes, Knowledge, and Uptake
Gurtej Malhi, Amir Rumman, Reka Thanabalan, Kenneth Croitoru, Mark S. Silverberg, A. Hillary Steinhart, Geoffrey C. Nguyen
Journal of Crohn's and Colitis.2015; 9(6): 439. CrossRef - Ideal Vaccination Strategy in Inflammatory Bowel Disease
Chang Kyun Lee
The Korean Journal of Gastroenterology.2015; 65(3): 159. CrossRef
- Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
- 6,192 View
- 81 Download
- 14 Web of Science
- 14 Crossref
Brief Communication
- Effect of Colostrum on the Symptoms and Mucosal Permeability in Patients with Irritable Bowel Syndrome: A Randomized Placebo-controlled Study
- Jin Young Yoon, Soo Jung Park, Jae Hee Cheon
- Intest Res 2014;12(1):80-82. Published online January 28, 2014
- DOI: https://doi.org/10.5217/ir.2014.12.1.80
-
PDFPubReader
-
Citations
Citations to this article as recorded by- Colostrum supplementation enhance mental health status and alleviate pain in patients with acetabular fracture: A randomized, controlled, clinical trial
Faezeh Gouhari, Reza Zandi, Shahin Talebi, Amir Mehrvar, Zahra Vahdat Shariatpanahi
Journal of Functional Foods.2024; 119: 106325. CrossRef - The Influence of Feeding with Colostrum and Colostrum Replacer on Major Blood Biomarkers and Growth Performance in Dairy Calves
Ramune Grigaleviciute, Rita Planciuniene, Ieva Prikockyte, Eivina Radzeviciute-Valciuke, Austeja Baleviciute, Augustinas Zelvys, Aukse Zinkeviciene, Vilma Zigmantaite, Audrius Kucinskas, Paulius Matusevicius, Povilas Kavaliauskas
Veterinary Sciences.2023; 10(2): 128. CrossRef
- Colostrum supplementation enhance mental health status and alleviate pain in patients with acetabular fracture: A randomized, controlled, clinical trial
- 7,928 View
- 44 Download
- 4 Web of Science
- 2 Crossref
Review
- The Medical Treatments of Intestinal Behçet's Disease: An Update
- Hye Won Lee, Won Ho Kim, Jae Hee Cheon
- Intest Res 2013;11(3):155-160. Published online July 30, 2013
- DOI: https://doi.org/10.5217/ir.2013.11.3.155
-
Abstract
PDF
- Behçet's disease (BD) is a systemic immunological disorder characterized by recurrent mucosal ulcerative lesions including oral and genital ulcerations in association with skin and ocular involvements. BD also can involve the gastrointestinal tract. Gastrointestinal involvement of BD is one of the major causes of morbidity and mortality for this disease. However, clinical data are quite limited because of the rarity of intestinal BD. Therefore, the management of intestinal BD is heavily dependent on expert opinions and standardized medical treatments of intestinal BD are yet to be established. In this brief review, the authors summarized the currently available medical treatments such as 5-aminosalicylic acids, corticosteroids, immuno-modulators, and anti-TNF agents. Moreover, we sought to suggest a treatment algorithm for intestinal BD based on the recently published and updated data. (Intest Res 2013;11:155-160)
-
Citations
Citations to this article as recorded by- Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef - Successful closure of ileostomy in a patient with intestinal Behçet's disease after therapy with adalimumab
Zhe Yan, Bei-Bei Cui, Yong-Yang Yu, Geng Yin, Xiao-Min Cen, Qi-Bing Xie
Medicine.2019; 98(9): e14624. CrossRef - Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease
Ippei Miyagawa, Kazuhisa Nakano, Shigeru Iwata, Shingo Nakayamada, Kazuyoshi Saito, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Akio Kawabe, Yusuke Miyazaki, Yoshiya Tanaka
Arthritis Research & Therapy.2019;[Epub] CrossRef - Herbal medicine for Behcet's disease
Ji Hee Jun, Tae-Young Choi, Junhua Zhang, Mi Mi Ko, Myeong Soo Lee
Medicine.2018; 97(13): e0165. CrossRef - Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef - Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease
Hyun Jung Lee, Jae Hyun Kim, Seung Won Kim, Hyun Ah Joo, Hye Won Lee, You Sun Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Young-Ho Kim, Jae Hee Cheon
Digestive Diseases and Sciences.2017; 62(8): 1953. CrossRef - Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?
Duk Hwan Kim, Jae Hee Cheon
Yonsei Medical Journal.2016; 57(1): 22. CrossRef - Postoperative Effects of Thiopurines in Patients with Intestinal Behçet’s Disease
Hye Won Lee, Jae Hee Cheon, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim
Digestive Diseases and Sciences.2015; 60(12): 3721. CrossRef - Leukopenia Predicts Remission in Patients with Inflammatory Bowel Disease and Behcet’s Disease on Thiopurine Maintenance
Mi Sung Park, Dong Hyun Kim, Duk Hwan Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Digestive Diseases and Sciences.2015; 60(1): 195. CrossRef - Overlooked Management and Risk Factors for Anemia in Patients with Intestinal Behçet’s Disease in Actual Clinical Practice
Bun Kim, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Tae Il Kim, Won Ho Kim
Gut and Liver.2015; 9(6): 750. CrossRef - Update on the Treatment of Intestinal Behçet's Disease
Kyung-Jo Kim
Journal of Rheumatic Diseases.2014; 21(4): 176. CrossRef - Mucosal Healing Predicts the Long-Term Prognosis of Intestinal Behçet’s Disease
Sun Mie Yim, Duk Hwan Kim, Hyun Jung Lee, Hui Won Jang, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Digestive Diseases and Sciences.2014; 59(10): 2529. CrossRef
- Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
- 2,649 View
- 29 Download
- 12 Crossref
Original Article
- The Rebleeding Risk and Prognostic Factors of Acute Hemorrhagic Rectal Ulcer
- Bun Kim, Min Seok Han, Dong Hoo Joh, Dong Jun Lee, Hye Sun Shin, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Tae Il Kim, Won Ho Kim
- Intest Res 2012;10(4):343-349. Published online October 31, 2012
- DOI: https://doi.org/10.5217/ir.2012.10.4.343
-
Abstract
PDF
- Background/Aims
Acute hemorrhagic rectal ulcer (AHRU) is an important etiology of lower gastrointestinal bleeding in intensive care unit patients and hospital inpatients. Moreover, with increasing elderly populations, and improved survival in critically ill patients, the incidence of AHRU has increased. The aim of this study is to determine rebleeding risk and prognostic factors of AHRU patients. Methods: We retrospectively reviewed 32 patients with AHRU in Severance Hospital from February 2006 to October 2010, collected clinical data, and analyzed their association with the recurrence of bleeding and mortality of patients. Results: The mean age of patients was 65.5 years, and 27 patients (84.4%) showed Eastern Cooperative Oncology Group performance status 3-4. Nineteen patients (59.4%) had recurrent bleeding. Hypoalbuminemia (≤2.5 g/dL) was a risk factor of rebleeding in univariate and multivariate analysis. For patients with chronic liver disease, hypoalbuminemia (≤2.5 g/dL), renal dysfunction (>2 mg/dL) and thrombocytopenia (<150,000/ՌL) showed relatively earlier rebleeding than those without (P=0.007, P=0.009, P=0.027 and P=0.043, respectively). The endoscopic hemostasis at the first bleeding event was associated with lower early rebleeding rate (P=0.048). In univariate analysis, chronic liver disease, hypoalbuminemia (≤2.5 g/dL) and the prolongation of activated partial thromboplastin time (>40 seconds) increased mortality (P=0.028, P=0.008 and P=0.027, respectively) and the patients with rebleeding showed a tendency toward higher mortality, compared to those without (57.9% vs. 23.1%, P=0.051). Conclusions: In AHRU patients, hypoalbuminemia was a risk factor of rebleeding, and chronic liver disease, hypoalbuminemia, renal dysfunction, thrombocytopenia and no endoscopic treatment at the first bleeding event was correlated with relatively earlier rebleeding. (Intest Res 2012;10:343-349) -
Citations
Citations to this article as recorded by- Rebleeding Risk of Acute Hemorrhagic Rectal Ulcer: A Multicenter Retrospective Study
Takahiro Muramatsu, Masakatsu Fukuzawa, Akira Madarame, Yasuyuki Kagawa, Miho Kikuchi, Sho Taniguchi, Satoshi Shimai, Sho Matsumoto, Fumito Yamanishi, Yuka Suzuki, Daiki Nemoto, Hirokazu Shinohara, Taisuke Matsumoto, Yohei Koyama, Kumiko Uchida, Hayato Ya
Internal Medicine.2024; 63(18): 2481. CrossRef - Acute hemorrhagic rectal ulcer syndrome: Comparison with non‐hemorrhagic rectal ulcer lower gastrointestinal bleeding
Joo Hyuk Jung, Jong Wook Kim, Hyun Woo Lee, Min Yong Park, Woo Hyun Paik, Won Ki Bae, Nam‐Hoon Kim, Kyung‐Ah Kim, June Sung Lee
Journal of Digestive Diseases.2017; 18(9): 521. CrossRef
- Rebleeding Risk of Acute Hemorrhagic Rectal Ulcer: A Multicenter Retrospective Study
- 2,342 View
- 18 Download
- 2 Crossref
Case Report
- Recurrent Acute Pericarditis Induced by 5-aminosalicylates in a Patient with Inflammatory Bowel Disease
- A Ra Choi, Mi Na Kim, Ji Hoon Lee, Yong Kang Lee, Yoon Hea Park, Hye Sun Shin, Tak Geun Oh, Hee Jin Park, Min Suk Park, Seungtaek Lim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
- Intest Res 2012;10(3):289-294. Published online July 31, 2012
- DOI: https://doi.org/10.5217/ir.2012.10.3.289
-
Abstract
PDF
- Inflammatory bowel disease (IBD) is an idiopathic chronic inflammation of the intestines. IBD treatment may require anti-inflammatory agents such as sulfasalazine or 5-aminosalicylate (5-ASA) and immunomodulators to control the symptoms. However, these agents have a variety of common adverse effects such as nausea, vomiting, skin rash, leukopenia, thrombocytopenia, and infections. Moreover, rare side effects such as nephrotic syndrome, pneumonitis, and pericarditis can occur. A 21-year-old male was admitted to the hospital due to acute chest pain, fever, and sweating. The patient had a history of Crohn's disease and had been taking mesalazine for 3 weeks. Chest x-ray, echocardiography, and clinical manifestations revealed that the patient had acute pericarditis. However, we did not recognize the relationship between these findings and 5-ASA at that time. Two years later, the patient took 5-ASA again, and similar symptoms occurred, which led us to confirm that he suffered from pericarditis induced by this drug. We report a case of acute recurrent pericarditis that developed after taking 5-ASA for IBD treatment with a review of the literature. (Intest Res 2012;10: 0-294)
- 2,427 View
- 15 Download
Special Review
- Guidelines for the Management of Crohn's Disease
- Byong Duk Ye, Suk-Kyun Yang, Sung Jae Shin, Kang Moon Lee, Byung Ik Jang, Jae Hee Cheon, Chang Hwan Choi, Young-Ho Kim, Heeyoung Lee, IBD Study Group of the Korean Association for the Study of Intestinal Diseases
- Intest Res 2012;10(1):26-66. Published online February 29, 2012
- DOI: https://doi.org/10.5217/ir.2012.10.1.26
-
Abstract
PDF
- Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with uncertain etiopathogenesis. CD can involve any site of gastrointestinal tract from the mouth to anus and is associated with serious complications such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies are currently applied for diverse clinical situations of CD. However, a lot of decisions on the management of CD are made depending on the personal experiences and choices of physicians. To suggest preferable approaches to diverse problems of CD and to minimize the variations according to physicians, guidelines for the management of CD are needed. Therefore, IBD Study Group of the Korean Association for the Study of the Intestinal Diseases has set out to develop the guidelines for the management of CD in Korea. These guidelines were developed using the adaptation methods and encompass the treatment of inflammatory disease, stricturing disease, and penetrating disease. The guidelines also cover the indication of surgery, prevention of recurrence after surgery, and CD in pregnancy and lactation. These are the first Korean guidelines for the management of CD and the update with further scientific data and evidences is needed. (Intest Res 2012;10:26-66)
-
Citations
Citations to this article as recorded by- Postoperative course of Crohn disease according to timing of bowel resection
Ji Min Lee, Kang-Moon Lee, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, Dong Soo Han, Chang Kyun Lee, Hyun-Ju Park
Medicine.2018; 97(16): e0459. CrossRef - Second Korean Guidelines for the Management of Crohn's Disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
The Korean Journal of Gastroenterology.2017; 69(1): 29. CrossRef - Second Korean guidelines for the management of Crohn's disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
Intestinal Research.2017; 15(1): 38. CrossRef - Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
Young Sun Kim, Sung-Ae Jung, Kang-Moon Lee, Soo Jung Park, Tae Oh Kim, Chang Hwan Choi, Hyun Gun Kim, Won Moon, Chang Mo Moon, Hye Kyoung Song, Soo-Young Na, Suk-Kyun Yang
Intestinal Research.2017; 15(3): 338. CrossRef - Computed Tomography Enterography and Magnetic Resonance Enterography in the Diagnosis of Crohn's Disease
Se Hyung Kim
Intestinal Research.2015; 13(1): 27. CrossRef - Crohn's Disease Clinical Network and Cohort (CONNECT) Study: The First Step Toward Nationwide Multicenter Research of Crohn's Disease in Korea
Jae Hee Cheon, You Sun Kim, Byong Duk Ye, Kang Moon Lee, Young Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
Intestinal Research.2014; 12(3): 173. CrossRef - Crohn's disease in Korea: past, present, and future
Kang-Moon Lee, Ji Min Lee
The Korean Journal of Internal Medicine.2014; 29(5): 558. CrossRef - Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine
Chang Kyun Lee, Hyun-Soo Kim, Byong Duk Ye, Kang-Moon Lee, You Sun Kim, Sang Youl Rhee, Hyo-Jong Kim, Suk-Kyun Yang, Won Moon, Ja-Seol Koo, Suck-Ho Lee, Geom Seog Seo, Soo Jung Park, Chang Hwan Choi, Sung-Ae Jung, Sung Noh Hong, Jong Pil Im, Eun Soo Kim
Journal of Crohn's and Colitis.2014; 8(5): 384. CrossRef - Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
Seong Yeon Jeong, Jeong Seop Moon, Kyu Joo Park, You Sun Kim
Intestinal Research.2014; 12(1): 74. CrossRef - Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
Nam Hee Kim, Yoon Suk Jung, Chang Mo Moon, Shin Yeong Lee, Eun Ran Kim, Young Ho Kim, Chang Kyun Lee, Suck Ho Lee, Jae Hak Kim, Kyu Chan Huh, Soon Man Yoon, Hyun Joo Song, Sun-Jin Boo, Hyun Joo Jang, You Sun Kim, Kang-Moon Lee, Jeong Eun Shin, Dong Il Par
Intestinal Research.2014; 12(4): 281. CrossRef - Clinical Outcome of Treatment with Infliximab in Crohn's Disease: A Single-Center Experience
Yeon-Ju Kim, Jung-Wook Kim, Chang Kyun Lee, Hyun Jin Park, Jae-Jun Shim, Jae Young Jang, Suk Ho Dong, Hyo Jong Kim, Byung-Ho Kim, Young Woon Chang
The Korean Journal of Gastroenterology.2013; 61(5): 270. CrossRef
- Postoperative course of Crohn disease according to timing of bowel resection
- 3,149 View
- 47 Download
- 11 Crossref
Original Articles
- The Clinical Utility of Positron Emission Tomography-computed Tomography in the Evaluation of Inflammatory Bowel Diseases
- Sung Ho Ryu, Jae Hee Cheon, Won Jun Kang, Jin Young Kim, Bo Kyung Kim, Jin Young Yoon, Yoon Suk Jung, Hyun Mi Heo, Jin Ha Lee, Soung Min Jeon, Sung Pil Hong, Tae Il Kim, Won Ho Kim
- Intest Res 2011;9(2):97-104. Published online August 30, 2011
- DOI: https://doi.org/10.5217/ir.2011.9.2.97
-
Abstract
PDF
- Background/Aims
Positron emission tomography-computed tomography (PET-CT) is a nuclear imaging technique that provides noninvasive, three dimensional, quantitative images. Recently, PET-CT has been shown to be valuable in assessing patients with inflammatory diseases; however, the clinical utility of PET-CT in the evaluation of inflammatory bowel disease (IBD) has not been defined. Thus, the aim of this study was to determine the clinical utility of PET-CT in the evaluation of IBD. Methods: Between November 2006 and September 2010, clinical, endoscopic, and radiological data on 14 patients (6 males and 8 females: age range, 33-79 years) with suspected IBD were collected. The standard work-up method for a definite diagnosis of IBD included ileocolonoscopy. Results: The 14 patients were divided into the following five groups: ulcerative colitis (n=4, 29%), intestinal Behcet's disease (n=3, 21%), intestinal tuberculosis (n=2, 14%), malignancy (n=2, 14%), and no abnormal findings with colonoscopy (n=3, 21%). A PET-CT based-diagnosis of IBD correlated with a colonoscopic diagnosis in nine cases (64.3%), but the matching ratio of the distribution of lesions between PET-CT findings and colonoscopic findings was only 18.1% (2/11). Conclusions: The utility of PET-CT in the diagnosis of IBD requires further evaluation. (Intest Res 2011;9:97-104)
- 2,445 View
- 15 Download
- The Early Diagnostic Accuracy for Gastrointestinal T-cell Lymphoma from a Perspective of Gastroenterologists
- Sung Ho Ryu, Jae Hee Cheon, Jin Young Kim, Bo Kyung Kim, Jin Young Yoon, Yoon Suk Jung, Hyun Mi Heo, Jin Ha Lee, Soung Min Jeon, Sung Pil Hong, Tae Il Kim, Won Ho Kim
- Intest Res 2011;9(1):19-26. Published online April 30, 2011
- DOI: https://doi.org/10.5217/ir.2011.9.1.19
-
Abstract
PDF
- Background/Aims
Primary T-cell lymphoma of the gastrointestinal tract is a very difficult disease entity to diagnose, and has an extremely poor prognosis. The aim of this study was to determine the early diagnostic accuracy for gastrointestinal T-cell lymphoma by gastroenterologists. Methods: Between January 2000 and October 2010, the clinical features of 15 patients with primary gastrointestinal T-cell lymphomas, including endoscopic findings, radiologic diagnosis, endoscopic biopsy findings, and final diagnosis, were retrospectively reviewed. Results: The most common initial presenting symptoms of primary gastrointestinal T-cell lymphomas was abdominal pain (n=11, 73%). The anatomic location of the primary lesion the small bowel (n=8, 53%), colon (n=5, 33%), and stomach (n=3, 20%). There were no cases of T-cell lymphomas diagnosed based on clinical symptoms, radiologic findings, or endoscopic findings without biopsy alone. Pathologic confirmation of T-cell lymphomas by endoscopic examination was achieved in 7 cases (64%) and the remaining cases (n=8, 53%) were diagnosed with T-cell lymphomas based on pathologic examination after surgery. Conclusions: All of the patients with primary T-cell lymphomas of the gastrointestinal tract were diagnosed exclusively by endoscopic or surgical pathologic examainations, suggesting that gastroenterologists should scrutinize and suspect this disease with caution due to atypical gastrointestinal ulcers. (Intest Res 2011;9: 6-26) -
Citations
Citations to this article as recorded by- Colonic Diffuse Large B-cell Lymphoma Hidden in Actinomycosis
Sang Hoon Lee, Seung-Joo Nam, Sung Joon Lee, Sung Chul Park, Chang Don Kang, Dae Hee Choi, Jin Myung Park, Seung Koo Lee
The Korean Journal of Gastroenterology.2019; 74(1): 46. CrossRef - A Case of Fungating Type Natural Killer Like T Cell Lymphoma of the Ascending Colon
Chang Seok Lee, Dong Hoon Shin, Cheol Woong Choi, Hyung Wook Kim, Dae Hwan Kang, Kyung Won Koh, Byoung Hoon Ji, Su Bum Park
The Korean Journal of Gastroenterology.2014; 64(4): 229. CrossRef
- Colonic Diffuse Large B-cell Lymphoma Hidden in Actinomycosis
- 2,526 View
- 18 Download
- 2 Crossref
Case Reports
- Colitis Cystica Profunda Masquerading as a Pneumatosis Cystoides Intestinalis: A Case Report
- Eun Suk Jung, Jae Hee Cheon, Kyong Joo Lee, Hyun Jung Lee, Hui Won Jang, Young Eun Chon, Kyu Sik Jung, Seonjung Chang, Sung Pil Hong, Tae Il Kim, Won Ho Kim
- Intest Res 2010;8(2):187-190. Published online December 30, 2010
- DOI: https://doi.org/10.5217/ir.2010.8.2.187
-
Abstract
PDF
- Colitis Cystica Profunda (CCP) is an uncommon and benign disease entity characterized by mucoid cysts located in the submucosal layer of the colon. It can mimic cystic submucosal tumors or mucinous adenocarcinoma and is usually located in the rectum. CCP is found in the ascending colon less frequently. CCP manifesting as multiple cystic tumors, similar to pneumatosis cystoides intestinalis, has not yet been reported. Recently, a case of CCP mimicking pneumatosis cystoides intestinalis in the ascending colon was treated. Here this case is reported and the literature reviewed. (Intest Res 2010;8:187-190)
- 2,366 View
- 28 Download
- Postradiation Malignant Fibrous Histiocytoma of the Colon: A Case Report
- Jin Young Yoon, Do Kyung Kim, Jae Hee Cheon, Chang Mo Moon, Jae Jun Park, Joo Won Chung, Eun Young Kim, Tae Hoon Kim, Chan Joo Lee, Eun Young Park, Sang Hoon Shin, Sung Pil Hong, Tae Il Kim, Nam Kyu Kim, Ho Guen Kim, Won Ho Kim
- Intest Res 2010;8(1):75-79. Published online June 30, 2010
- DOI: https://doi.org/10.5217/ir.2010.8.1.75
-
Abstract
PDF
- Post-radiation soft tissue sarcomas are recognized as rare complications of radiation therapy. The most common type of post-radiation soft tissue sarcoma is a malignant fibrous histiocytoma (MFH), which originates from mesenchymal cells with a predominance of histiocytes and fibroblasts. The two most common sites of occurrence for post-radiation soft tissue sarcomas are the chest wall and pelvic cavity. Post-radiation colorectal MFHs are extremely rare and all of the reported cases of post-radiation sarcomas have occurred ＞3 years after radiation therapy. Recently, we managed a case of colorectal MFH which developed in a 48-year-old male who had undergone a low anterior resection for rectal adenocarcinoma and had received chemoradiotherapy as adjuvant treatment. Twelve months after radiotherapy, a 4 cm mass was detected 8 cm superior to the anastomosis site on colonoscopic examination. A soft tissue sarcoma was suspected on pathologic examination of the biopsy specimen. Therefore, he underwent a Hartmann's operation and the final pathologic finding revealed MFH with a storiform pattern of tumor cells composed of pleomorphic, multinucleated giant cells. This is the first case of MFH that had a latency period ＜3 years (i.e., 1 year) between the time of radiotherapy and diagnosis. (Intest Res 2010;8:75-79)
- 2,417 View
- 14 Download
- Clinical Experience of Thalidomide in the Treatment of Korean Patients with Intestinal BehcӇet's Disease: Pilot Experience in a Single Center
- Hyun Jung Lee, Jae Hee Cheon, Kyong Joo Lee, Hui Won Jang, Kyu Sik Jung, Eun Suk Jung, Jin Ha Lee, Seung Min Jeon, Sung Pil Hong, Tae Il Kim, Won Ho Kim
- Intest Res 2010;8(1):63-69. Published online June 30, 2010
- DOI: https://doi.org/10.5217/ir.2010.8.1.63
-
Abstract
PDF
- Intestinal BehcӇet's disease (BD) often leads to severe complications, such as perforation or massive bleeding, and therefore is one of the major causes of morbidity and mortality. As thalidomide has been identified and its anti-inflammatory and immunomodulatory properties clarified, this drug has been used in cases of systemic BD with some success. Herein we report a case series of four patients with intestinal BD to share our clinical experience with thalidomide treatment. We studied the effects of thalidomide in four patients who had a chronic relapse of intestinal BD requiring the frequent use of systemic steroids due to refractoriness to prior treatments, such as 5-aminosalycylic acid and immunosuppressants. Pre- and post-treatment clinical and laboratory data, including clinical symptoms, laboratory data, disease activity index for intestinal BD, and thalidomide toxicity were recorded. Three of the four patients had a clinical and radiologic improvement after thalidomide treatment and all of the patients discontinued steroid therapy. Although two patients tolerated thalidomide, two patients could not continue the treatment because they suffered from edema and neutropenia. Thalidomide could be considered a therapeutic option for the treatment of intestinal BD. (Intest Res 2010;8:63-69)
-
Citations
Citations to this article as recorded by- Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef - An Overview of Conventional and Recent Treatment Options for Behcet’s Disease
Kader Cetin Gedik, Micol Romano, Roberta A. Berard, Erkan Demirkaya
Current Treatment Options in Rheumatology.2020; 6(2): 99. CrossRef - Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef - Update on the Medical Management of Gastrointestinal Behçet’s Disease
Giuseppe Lopalco, Donato Rigante, Vincenzo Venerito, Claudia Fabiani, Rossella Franceschini, Michele Barone, Giovanni Lapadula, Mauro Galeazzi, Bruno Frediani, Florenzo Iannone, Luca Cantarini
Mediators of Inflammation.2017; 2017: 1. CrossRef - An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease
Jae Hee Cheon, Won Ho Kim
Current Opinion in Rheumatology.2015; 27(1): 24. CrossRef - Update on the Treatment of Intestinal Behçet's Disease
Kyung-Jo Kim
Journal of Rheumatic Diseases.2014; 21(4): 176. CrossRef - The Medical Treatments of Intestinal Behçet's Disease: An Update
Hye Won Lee, Won Ho Kim, Jae Hee Cheon
Intestinal Research.2013; 11(3): 155. CrossRef - Efficacy of Infliximab in Intestinal Behçet’s Disease
Jin Ha Lee, Jae Hee Cheon, Seong Woo Jeon, Byong Duk Ye, Suk-Kyun Yang, Young-Ho Kim, Kang-Moon Lee, Jong Pil Im, Joo Sung Kim, Chang Kyun Lee, Hyo Jong Kim, Eun Young Kim, Kyeong Ok Kim, Byung Ik Jang, Won Ho Kim
Inflammatory Bowel Diseases.2013; : 1. CrossRef
- Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
- 2,638 View
- 28 Download
- 8 Crossref
First
Prev
